辉瑞中国区副总裁、肿瘤事业部总经理王玉认为，创新治疗方案只是攻克癌症的一环，在中国，提高公众防癌意识、探索灵活支付方式、提升场景化医疗服务都大有可为。

(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

Most common AE is myelosuppression, GI side effect, and transient hypertension. There were no treatment-related deaths. Results are consistent with the data reported on the first 19 patients in Study ...

Incorporating perioperative durvalumab into treatment with neoadjuvant chemotherapy and radical cystectomy prolongs ...

Financial stability risks remain contained in the near term, although rising economic and geopolitical uncertainty increases the likelihood of adverse shocks, exposing fragilities. Chapter 1 of the ...

在市场信心的显著表现中，Natera Inc. (NTRA)股价已达到历史新高，飙升至133.64美元。这一里程碑凸显了该公司在基因检测和诊断领域的显著增长期。过去一年，Natera的股票价值飙升，一年变化率高达193.19%。这一激增反映了投资者对公司创新产品线的乐观态度，以及其在快速增长的基因检测市场中获得更大份额的潜力。这一历史新高不仅代表了Natera股票表现的巅峰，也证明了公司持续推动其 ...

近日， 迪哲医药 举办2024年第三季度业绩说明会。会上，迪哲医药管理层表示，公司高度重视并积极参与了舒沃哲®和高瑞哲®的国家医保谈判工作，具体谈判情况请关注有关部门公示或公告。 本次医保谈判我们感受到国家医保对国产原创新药的大力支持，将带动创新药行业的进一步发展，公司将继续加快全球原创新药的研发。

由安徽医科大学第一附属医院、蚌埠医学院第一附属医院、安徽省公共卫生临床中心、泰莱生物合著的学术成果《血浆游离 5-羟甲基胞嘧啶：高潜力的胃肠癌症无创检测生物标志物》被 ESMO ASIA 收录，刊载于 Annals of Oncology 中 ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

ECHO, a proprietary diagnostic for detection of ecDNA amplified oncogenes In September, analytical validation data was presented at the European Society for Medical Oncology (ESMO) Congress for the ...